Cornelius Lewis

King's College Hospital

Papers

1

Total Citations

12

H-Index

1

About

Cornelius Lewis is a leading clinical researcher in ophthalmology, whose work centers on innovative treatments for neovascular age-related macular degeneration (nAMD), a primary cause of blindness worldwide. His most significant contribution is the pivotal STAR trial, a randomized, double-masked, sham-controlled device study evaluating stereotactic radiotherapy as a novel therapy for nAMD. This landmark work demonstrated that ionising radiation can effectively mitigate key pathogenic processes underlying the disease, offering a potential alternative to the standard-of-care anti-VEGF injections. The STAR trial, published in 2024 with 12 citations, has already shaped discussions on reducing treatment burden for patients. Lewis’s research bridges radiation oncology and retinal disease, showcasing his ability to translate mechanistic insights into rigorous clinical evidence. His work is distinguished by its focus on device-based interventions that could transform chronic disease management. For students and researchers, Lewis exemplifies how targeted, hypothesis-driven trials can challenge therapeutic paradigms, offering hope for more durable and less invasive solutions in age-related blindness.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 46
🏛 Institutions: King's College Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago